Novartis’ MS Drug Patent Upheld And Generic Ruled Infringing

Novartis Pharmaceuticals Corp. beat back a challenge to its blockbuster multiple sclerosis drug Gilenya in a Delaware federal court ruling unsealed on Monday, with the judge finding Novartis’ patent valid and holding that a planned generic by HEC Pharm infringed…

Read this piece in its entirety at Law360.

Comments

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s